Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV - Seite 3

In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date after the date hereof.

Investors:

Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
[phone]

LifeSci Advisors, LLC
Ashley R. Robinson
[phone]
[e-mail] 

Media:

McNeil, Gray & Rice
Kristin Nugent
Senior Account Supervisor
[phone]

Source: Spring Bank Pharmaceuticals, Inc